ALK-Abelló A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKABY research report →
Companywww.alk.net
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies.
- CEO
- Carsten Hellmann
- IPO
- 2013
- Employees
- 2,566
- HQ
- Horsholm, DK
Valuation
- Market Cap
- $0
- P/E
- 44.59
- P/S
- 8.70
- P/B
- 8.69
- EV/EBITDA
- 26.70
- Div Yield
- 0.62%
Profitability
- Gross Margin
- 67.76%
- Op Margin
- 26.73%
- Net Margin
- 19.51%
- ROE
- 20.45%
- ROIC
- 16.25%
Growth & Income
- Revenue
- $3.92B · 12.17%
- Net Income
- $219.00M · 776.00%
- EPS
- $1.00 · 809.09%
- Op Income
- $302.00M
- FCF YoY
- 159.49%
Performance & Tape
- 52W High
- $104.38
- 52W Low
- $31.01
- 50D MA
- $85.26
- 200D MA
- $87.04
- Beta
- 0.43
- Avg Volume
- 23
Get TickerSpark's AI analysis on AKABY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AKABY Coverage
We haven't published any research on AKABY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AKABY Report →